436 related articles for article (PubMed ID: 20443663)
1. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
5. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
Langley RG; Gupta AK; Cherman AM; Inniss KA
J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
[TBL] [Abstract][Full Text] [Related]
7. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
[TBL] [Abstract][Full Text] [Related]
8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
10. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
12. Biologic agents in the treatment of psoriasis.
Guarneri F; Guarneri C; Guarneri B
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
14. [Biologic therapies in the treatment of psoriasis].
Farhi D; Dupin N
Presse Med; 2009 May; 38(5):832-43. PubMed ID: 19282134
[TBL] [Abstract][Full Text] [Related]
15. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
16. A new era in the management of psoriasis? The biologics: facts and controversies.
Ferrándiz C; Carrascosa JM; Boada A
Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
[TBL] [Abstract][Full Text] [Related]
17. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
18. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
Graves JE; Nunley K; Heffernan MP
J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
[TBL] [Abstract][Full Text] [Related]
19. New treatments for psoriasis: which biologic is best?
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2006; 17(2):96-107. PubMed ID: 16766334
[TBL] [Abstract][Full Text] [Related]
20. A review of biologic treatments for psoriasis with emphasis on infliximab.
Pirzada S; Tomi Z; Gulliver W
Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
